EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease

Steven E Arnold iD, Bradley T Hyman, Rebecca A Betensky, Hiroko H Dodge

Alzheimer's & Dementia · 2024-10 · 20 (10) · 7384-7394

DOI: 10.1002/alz.14063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 06.09.2024. Verfasst von Steven E Arnold und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Precision Medicine. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Challenger Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biological and clinical heterogeneity is a major challenge in research for developing new treatments for Alzheimer's disease (AD). AD may be defined by its amyloid beta and tau pathologies, but we recognize that mixed pathologies are common, and that diverse genetics, central nervous system (CNS) and systemic pathophysiological processes, and environmental/experiential factors contribute to AD's diverse clinical and neuropathological features. All these factors are rational targets for therapeutic development; indeed, there are hundreds of candidate pharmacological, dietary, neurostimulation, and lifestyle interventions that show benefits in homogeneous laboratory models. Conventional clinical trial designs accommodate heterogeneity poorly, and this may be one reason that progress in translating candidate interventions has been so difficult. We review the challenges of AD's heterogeneity for the clinical trials enterprise. We then discuss how advances in repeatable biomarkers and digital phenotyping enable novel “single‐case” and adaptive trial designs to accelerate therapeutics development, moving us closer to personalized research and medicine for AD. Highlights Alzheimer's disease is diverse in its clinical features, course, risks, and biology. Typical randomized controlled trials are exclusive and necessarily large to attain arm comparability with broad outcomes. Repeated blood biomarkers and digital tracking can improve outcome measure precision and sensitivity. This enables the use of novel “single‐case” and adaptive trial designs for inclusivity, rigor, and efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePrecision MedicineHumansBiomarkersClinical Trials as TopicAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Alzheimer's diseaseamyloidbiomarkersclinical trialscombination therapyco‐morbiditiesdementiadigital healthheterogeneityinflammationpersonalized medicinerisk factorstau

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Biostatistics, New York University School of Global Public Health, New York, New York, USA.

ORCID-Profile: Steven E Arnold

Förderung

  • NIA NIH HHS
  • NIH HHS
  • Challenger Foundation
  • National Institutes of Health

Zitieren

APA

Arnold, S. E., Hyman, B. T., Betensky, R. A., & Dodge, H. H. (2024). Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease. Alzheimer's & Dementia, 20(10), 7384-7394. https://doi.org/10.1002/alz.14063

Vancouver

Arnold SE, Hyman BT, Betensky RA, Dodge HH. Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease. Alzheimer's & Dementia. 2024;20(10):7384-7394. doi:10.1002/alz.14063

BibTeX
@article{Arnold2024,
  author = {Arnold, Steven E and Hyman, Bradley T and Betensky, Rebecca A and Dodge, Hiroko H},
  title = {Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {10},
  pages = {7384--7394},
  doi = {10.1002/alz.14063}
}
Kostenlos starten →